Pricing Strategies

In a case that could have significant ramifications for the scope of the US False Claims Act, the US Supreme Court has agreed to remand for further proceedings allegations that supermarket and pharmacy chains defrauded the government via low-cost drug programs.

Coherus BioSciences had teased a “compelling value proposition” for its Yusimry (adalimumab-aqvh) biosimilar to AbbVie’s Humira blockbuster and it has delivered, with a pair of pricing strategies include one though an alliance with self-labelled “disruptor” Mark Cuban.

Ivabradine stood out among recently-launched UK generics with an average price rise of more than a third in April, according to the latest figures from market researcher WaveData.

Samsung Bioepis has published the first in a planned series of reports on the US biosimilars market, including insights into pricing, uptake and market share for various biosimilars.

A US Senate Finance Committee has heard divided opinions on the impact of vertical integration among pharmacy benefit managers, with one witness maintaining it may have positive competitive consequences while another condemned the practice outright.

By launching a bid for judicial review of its exclusion from UK negotiations over the VPAS rebate scheme, the BGMA has thrust itself into conflict with the country’s government as well as local brand industry association the ABPI.

Witnesses at a US Senate Finance Committee Hearing have condemned the impact the “perverse” practices of pharmacy benefit managers have on off-patent drugs, often placing them on non-preferred tiers so that patients must use more expensive, branded medication.

Cigna’s PBM, Express Scripts, is looking to “further align incentives across the pharmaceutical supply chain, consumers, and clients,” with a trio of new products available starting this summer.

Two products featured highly among the fastest-rising UK generics prices in March, but for different reasons.